{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:11:07Z","timestamp":1794978667684,"version":"4.9.1"},"reference-count":45,"publisher":"Pacini Editore","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Otorhinolaryngol Ital"],"DOI":"10.14639\/0392-100x-n1911","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T07:16:56Z","timestamp":1658819816000},"page":"199-204","source":"Crossref","is-referenced-by-count":12,"title":["Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review","Effetti avversi di dupilumab nel trattamento della rinosinusite cronica con poliposi nasale"],"prefix":"10.14639","volume":"42","author":[{"given":"Letizia","family":"Nitro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Mario","family":"Bulfamante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Maria","family":"Saibene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Arnone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Felisati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Pipolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"20340","published-online":{"date-parts":[[2022,6]]},"reference":[{"key":"10.14639\/0392-100X-N1911_ref1","doi-asserted-by":"crossref","unstructured":"Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012;50:1-12. https:\/\/doi.org\/10.4193\/Rhino12.000","DOI":"10.4193\/Rhino12.000"},{"key":"10.14639\/0392-100X-N1911_ref2","doi-asserted-by":"crossref","unstructured":"Jarvis D, Newson R, Lotvall J, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy 2012;67:91-98. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02709.x","DOI":"10.1111\/j.1398-9995.2011.02709.x"},{"key":"10.14639\/0392-100X-N1911_ref3","doi-asserted-by":"crossref","unstructured":"Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe-an underestimated disease. A GA2LEN study. Allergy 2011;66:1216-1223. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02646.x","DOI":"10.1111\/j.1398-9995.2011.02646.x"},{"key":"10.14639\/0392-100X-N1911_ref4","doi-asserted-by":"crossref","unstructured":"Chung JH, Lee YJ, Kang TW, et al. Altered quality of life and psychological health (SCL-90-R) in patients with chronic rhinosinusitis with nasal polyps. Ann Otol Rhinol Laryngol 2015;124:663-670. https:\/\/doi.org\/10.1177\/000348941557618","DOI":"10.1177\/0003489415576181"},{"key":"10.14639\/0392-100X-N1911_ref5","doi-asserted-by":"crossref","unstructured":"Bhattacharyya N, Villeneuve S, Joish VN, et al. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope 2019;129:1969-1975. https:\/\/doi.org\/10.1002\/lary.27852","DOI":"10.1002\/lary.27852"},{"key":"10.14639\/0392-100X-N1911_ref6","doi-asserted-by":"crossref","unstructured":"Bachert C, Bhattacharyya N, Desrosiers M, et al. Burden of disease in chronic rhinosinusitis with nasal polyps. J Asthma Allergy 2021;14:127-134. https:\/\/doi.org\/10.2147\/JAA.S290424","DOI":"10.2147\/JAA.S290424"},{"key":"10.14639\/0392-100X-N1911_ref7","doi-asserted-by":"crossref","unstructured":"Jonstam K, Swanson BN, Mannent LP, et al. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy 2019;74:743-752. https:\/\/doi.org\/10.1111\/all.13685","DOI":"10.1111\/all.13685"},{"key":"10.14639\/0392-100X-N1911_ref8","doi-asserted-by":"crossref","unstructured":"Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-2466. https:\/\/doi.org\/10.1056\/NEJMoa1304048","DOI":"10.1056\/NEJMoa1304048"},{"key":"10.14639\/0392-100X-N1911_ref9","unstructured":"European Medicines Agency. Annex I. Summary of product characteristics [dupilumab]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf. Accessed on 19 September 2019."},{"key":"10.14639\/0392-100X-N1911_ref10","doi-asserted-by":"crossref","unstructured":"Bachert C, Zhang N, Cavaliere C, et al. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2020;145:725-739. https:\/\/doi.org\/10.1016\/j.jaci.2020.01.020","DOI":"10.1016\/j.jaci.2020.01.020"},{"key":"10.14639\/0392-100X-N1911_ref11","doi-asserted-by":"crossref","unstructured":"Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol 2015;136:1431-1440. https:\/\/doi.org\/10.1016\/j.jaci.2015.10.010","DOI":"10.1016\/j.jaci.2015.10.010"},{"key":"10.14639\/0392-100X-N1911_ref12","doi-asserted-by":"crossref","unstructured":"Halling A-S, Loft N, Silverberg JI, et al. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol 2021;84:139-147. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.051","DOI":"10.1016\/j.jaad.2020.08.051"},{"key":"10.14639\/0392-100X-N1911_ref13","doi-asserted-by":"crossref","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017;389:2287-2303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"10.14639\/0392-100X-N1911_ref14","doi-asserted-by":"crossref","unstructured":"Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016;388:31-44. https:\/\/doi.org\/10.1016\/S0140-6736(16)30307-5","DOI":"10.1016\/S0140-6736(16)30307-5"},{"key":"10.14639\/0392-100X-N1911_ref15","doi-asserted-by":"crossref","unstructured":"Kartush AG, Schumacher JK, Shah R, et al. Biologic agents for the treatment of chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy 2019;33:203-211. https:\/\/doi.org\/10.1177\/1945892418814768","DOI":"10.1177\/1945892418814768"},{"key":"10.14639\/0392-100X-N1911_ref16","doi-asserted-by":"crossref","unstructured":"Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 2019;74:2312-2319. https:\/\/doi.org\/10.1111\/all.13875","DOI":"10.1111\/all.13875"},{"key":"10.14639\/0392-100X-N1911_ref17","doi-asserted-by":"crossref","unstructured":"Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016;315:469-479. https:\/\/doi.org\/10.1001\/jama.2015.19330","DOI":"10.1001\/jama.2015.19330"},{"key":"10.14639\/0392-100X-N1911_ref18","doi-asserted-by":"crossref","unstructured":"Gallo S, Russo F, Mozzanica F, et al. Prognostic value of the Sinonasal Outcome Test 22 (SNOT-22) in chronic rhinosinusitis. Acta Otorhinolaryngol Ital 2020;40:113-121. https:\/\/doi.org\/10.14639\/0392-100X-N0364","DOI":"10.14639\/0392-100X-N0364"},{"key":"10.14639\/0392-100X-N1911_ref19","doi-asserted-by":"crossref","unstructured":"Busse W, Maspero JF, Katelaris CH, et al. Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS\/NP) in LIBERTY ASTHMA QUEST. Eur Respir J 2018;52. http:\/\/doi.org\/10.1183\/13993003.congress-2018.PA1125","DOI":"10.1183\/13993003.congress-2018.PA1125"},{"key":"10.14639\/0392-100X-N1911_ref20","doi-asserted-by":"crossref","unstructured":"Bachert C, Hellings PW, Mullol J, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy 2020;75:148-157. https:\/\/doi.org\/10.1111\/all.13984","DOI":"10.1111\/all.13984"},{"key":"10.14639\/0392-100X-N1911_ref21","doi-asserted-by":"crossref","unstructured":"Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019;394:1638-1650. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"10.14639\/0392-100X-N1911_ref22","doi-asserted-by":"crossref","unstructured":"Chong L-Y, Piromchai P, Sharp S, et al. Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev 2020;2:CD013513. https:\/\/doi.org\/10.1002\/14651858.CD013513.pub2","DOI":"10.1002\/14651858.CD013513.pub2"},{"key":"10.14639\/0392-100X-N1911_ref23","doi-asserted-by":"crossref","unstructured":"Bachert C, Zinreich SJ, Hellings PW, et al. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology 2020;58:10-17. https:\/\/doi.org\/10.4193\/Rhin18.282","DOI":"10.4193\/Rhin18.282"},{"key":"10.14639\/0392-100X-N1911_ref24","doi-asserted-by":"crossref","unstructured":"Iqbal IZ, Kao SS-T, Ooi EH. The role of biologics in chronic rhinosinusitis: a systematic review. Int Forum Allergy Rhinol 2020;10:165-174. https:\/\/doi.org\/10.1002\/alr.22473","DOI":"10.1002\/alr.22473"},{"key":"10.14639\/0392-100X-N1911_ref25","doi-asserted-by":"crossref","unstructured":"Desrosiers M, Mannent LP, Amin N, et al. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. Rhinology 2021;59:301-311. https:\/\/doi.org\/10.4193\/Rhin20.415","DOI":"10.4193\/Rhin20.415"},{"key":"10.14639\/0392-100X-N1911_ref26","doi-asserted-by":"crossref","unstructured":"Mullol J, Laidlaw TM, Bachert C, et al. Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials. Allergy 2022;77:1231-1244. https:\/\/doi.org\/10.1111\/all.15067","DOI":"10.1111\/all.15067"},{"key":"10.14639\/0392-100X-N1911_ref27","doi-asserted-by":"crossref","unstructured":"Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018;378:2486-2496. https:\/\/doi.org\/10.1056\/NEJMoa1804092","DOI":"10.1056\/NEJMoa1804092"},{"key":"10.14639\/0392-100X-N1911_ref28","doi-asserted-by":"crossref","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019;181:459-473. https:\/\/doi.org\/10.1111\/bjd.17869","DOI":"10.1111\/bjd.17869"},{"key":"10.14639\/0392-100X-N1911_ref29","doi-asserted-by":"crossref","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016;375:2335-2348. https:\/\/doi.org\/10.1056\/NEJMoa1610020","DOI":"10.1056\/NEJMoa1610020"},{"key":"10.14639\/0392-100X-N1911_ref30","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 2019;143:155-172. https:\/\/doi.org\/10.1016\/j.jaci.2018.08.022","DOI":"10.1016\/j.jaci.2018.08.022"},{"key":"10.14639\/0392-100X-N1911_ref31","doi-asserted-by":"crossref","unstructured":"Seegr\u00e4ber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 2018;11:467-474. https:\/\/doi.org\/10.1080\/17512433.2018.1449642","DOI":"10.1080\/17512433.2018.1449642"},{"key":"10.14639\/0392-100X-N1911_ref32","doi-asserted-by":"crossref","unstructured":"Gooderham MJ, Hong HC-H, Eshtiaghi P, et al. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 2018;78:S28-36. https:\/\/doi.org\/10.1016\/j.jaad.2017.12.022","DOI":"10.1016\/j.jaad.2017.12.022"},{"key":"10.14639\/0392-100X-N1911_ref33","doi-asserted-by":"crossref","unstructured":"Tha\u00e7i D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016;387:40-52. https:\/\/doi.org\/10.1016\/S0140-6736(15)00388-8","DOI":"10.1016\/S0140-6736(15)00388-8"},{"key":"10.14639\/0392-100X-N1911_ref34","doi-asserted-by":"crossref","unstructured":"Fargnoli MC, Esposito M, Ferrucci S, et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat 2021;32:507-513. https:\/\/doi.org\/10.1080\/09546634.2019.1682503","DOI":"10.1080\/09546634.2019.1682503"},{"key":"10.14639\/0392-100X-N1911_ref35","doi-asserted-by":"crossref","unstructured":"de Wijs LEM, Nguyen NT, Kunkeler ACM, et al. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol 2020;183:745-749. https:\/\/doi.org\/10.1111\/bjd.18730","DOI":"10.1111\/bjd.18730"},{"key":"10.14639\/0392-100X-N1911_ref36","doi-asserted-by":"crossref","unstructured":"Thibodeaux Q, Smith MP, Ly K, et al. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother 2019;15:2129-2139. https:\/\/doi.org\/10.1080\/21645515.2019.1582403","DOI":"10.1080\/21645515.2019.1582403"},{"key":"10.14639\/0392-100X-N1911_ref37","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Ariens L, Thurau S, et al. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract 2018;6:1778-1780.e1. https:\/\/doi.org\/10.1016\/j.jaip.2018.01.034","DOI":"10.1016\/j.jaip.2018.01.034"},{"key":"10.14639\/0392-100X-N1911_ref38","doi-asserted-by":"crossref","unstructured":"Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018;378:2475-2485. https:\/\/doi.org\/10.1056\/NEJMoa1804093","DOI":"10.1056\/NEJMoa1804093"},{"key":"10.14639\/0392-100X-N1911_ref39","doi-asserted-by":"crossref","unstructured":"Busse WW, Maspero JF, Rabe KF, et al. Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther 2018;35:737-748. https:\/\/doi.org\/10.1007\/s12325-018-0702-4.","DOI":"10.1007\/s12325-018-0702-4"},{"key":"10.14639\/0392-100X-N1911_ref40","doi-asserted-by":"crossref","unstructured":"Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy 2020;75:1023-1042. https:\/\/doi.org\/10.1111\/all.14221","DOI":"10.1111\/all.14221"},{"key":"10.14639\/0392-100X-N1911_ref41","doi-asserted-by":"crossref","unstructured":"Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716-725. https:\/\/doi.org\/10.1038\/nm.2678","DOI":"10.1038\/nm.2678"},{"key":"10.14639\/0392-100X-N1911_ref42","doi-asserted-by":"crossref","unstructured":"Bachert C, Hellings PW, Mullol J, et al. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol Pract 2019;7:2447-2449.e2. https:\/\/doi.org\/10.1016\/j.jaip.2019.03.023","DOI":"10.1016\/j.jaip.2019.03.023"},{"key":"10.14639\/0392-100X-N1911_ref43","doi-asserted-by":"crossref","unstructured":"Kim J, Naclerio R. Therapeutic potential of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps: evidence to date. Ther Clin Risk Manag 2020;16:31-37. https:\/\/doi.org\/10.2147\/TCRM.S210648","DOI":"10.2147\/TCRM.S210648"},{"key":"10.14639\/0392-100X-N1911_ref44","doi-asserted-by":"crossref","unstructured":"Deleuran M, Tha\u00e7i D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol 2020;82:377-388. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.074","DOI":"10.1016\/j.jaad.2019.07.074"},{"key":"10.14639\/0392-100X-N1911_ref45","unstructured":"FDA. Dupixent\u00ae (dupilumab) injection, for subcutaneous use: US prescribing information, 2017. US Food and Drug Administration (https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761055lbl.pdf). Accessed on March 2017."}],"container-title":["Acta Otorhinolaryngologica Italica"],"original-title":[],"link":[{"URL":"https:\/\/www.actaitalica.it\/article\/view\/1911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T07:19:56Z","timestamp":1729667996000},"score":1,"resource":{"primary":{"URL":"https:\/\/old.actaitalica.it\/article\/view\/1911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6]]}},"URL":"https:\/\/doi.org\/10.14639\/0392-100x-n1911","relation":{},"ISSN":["1827-675X"],"issn-type":[{"value":"1827-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"article-number":"1"}}